Metformin Attenuates Liver Fat Content: Finding from Schizophrenia Patients with Olanzapine-induced Weight Gain

다국어 초록 (Multilingual Abstract)

Objective: This study was performed to evaluate the efficacy of metformin on liver fat content (LFC) in first episode schizophrenia patients with olanzapine-induced weight gain, and the relationship between the change of LFC and the other metabolic indices.
Methods: In a double-blind study, the clinically stable inpatients with first-episode schizophrenia under olanzapine monotherapy who gained more than 7% of their baseline weight were randomly assigned to two groups; one with olanzapine plus metformin (1,000 mg/day) (metformin group) and the other with olanzapine plus placebo (placebo group) for 16 weeks. All patients continued to maintain the original olanzapine dosage. LFC was measured by magnetic resonance imaging at baseline and at the end of 16 weeks, respectively. At the same time, glucose and lipid metabolism, homeostasis model assessment of insulin resistance index (HOMA-IR) were measured respectively, analyzing the correlation between the change value of LFC and other indicators.
Results: Over the 16-week study period, LFC value in metformin group decreased compared with baseline. LFC change across the 16-week treatment period was −2.91% for the metformin group and 0.59% for the placebo group, with a between-group difference of −3.5% (95% confidence interval, −6.08 to −0.93; p = 0.009). Compared to baseline, in the metformin group, triglyceride and HOMA-IR reduced significantly, while high density lipoprotein cholesterol increased significantly at weeks 16. There was positive correlation between LFC changes and triglycerides, HOMA-IR changes significantly.
Conclusion: Metformin can significantly attenuate LFC in schizophrenia patients with olanzapine-induced weight gain.
It may be related to the improvement of the part of the glucolipid metabolic indices

참고문헌 (Reference)

1 Eckel RH, "The metabolic syndrome" 365 : 1415-1428, 2005

2 Wulffelé MG, "The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus : a systematic review" 256 : 1-14, 2004

3 Ehret M, "The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents : a meta-analysis" 71 : 1286-1292, 2010

4 Lichtenstein AH, "Summary of American Heart Association diet and lifestyle recommendations revision 2006" 26 : 2186-2191, 2006

5 Linder K, "Relationships of body composition and liver fat content with insulin resistance in obesity-matched adolescents and adults" 22 : 1325-1331, 2014

6 Targher G, "Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2diabetic patients" 30 : 1212-1218, 2007

7 Coccurello R, "Potential mechanisms of atypical antipsychotic-induced metabolic derangement : clues for understanding obesity and novel drug design" 127 : 210-251, 2010

8 Rector RS, "Non-alcoholic fatty liver disease and the metabolic syndrome : an update" 14 : 185-192, 2008

9 Chen WL, "Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens" 671 : 107-112, 2011

10 Geerling JJ, "Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice" 63 : 880-891, 2014

11 Jarskog LF, "Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder" 170 : 1032-1040, 2013

12 Wang M, "Metformin for treatment of antipsychotic-induced weight gain : a randomized, placebo-controlled study" 138 : 54-57, 2012

13 Wu RR, "Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia : a double-blind, randomized, placebo-controlled study" 169 : 813-821, 2012

14 Praharaj SK, "Metformin for olanzapine-induced weight gain : a systematic review and metaanalysis" 71 : 377-382, 2011

15 Chen CH, "Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine" 32 : 925-931, 2008

16 De Hert M, "Metabolic and cardiovascular adverse effects associated with antipsychotic drugs" 8 : 114-126, 2011

17 Chan DC, "Measurement of liver fat by magnetic resonance imaging : relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men" 8 : 698-702, 2006

18 Maayan L, "Management of antipsychotic-related weight gain" 10 : 1175-1200, 2010

19 Yang J, "Long-term metformin treatment stimulates cardiomyocyte glucose transport through an AMP-activated protein kinase-dependent reduction in GLUT4 endocytosis" 147 : 2728-2736, 2006

20 Parikh RM, "Index of central obesity-a novel parameter" 68 : 1272-1275, 2007

21 Kotronen A, "Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes" 135 : 122-130, 2008

22 Cassidy FH, "Fatty liver disease : MR imaging techniques for the detection and quantification of liver steatosis" 29 : 231-260, 2009

23 Newall H, "Efficacy of metformin for prevention of weight gain in psychiatric populations : a review" 27 : 69-75, 2012

24 Ellinger LK, "Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain" 44 : 668-679, 2010

25 Byrne CD, "Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease : implications for cardiovascular disease" 34 : 1155-1161, 2014

26 Byrne CD, "Ectopic fat, insulin resistance and non-alcoholic fatty liver disease" 72 : 412-419, 2013

27 Byrne CD, "Dorothy Hodgkin Lecture 2012 : non-alcoholic fatty liver disease, insulin resistance and ectopic fat : a new problem in diabetes management" 29 : 1098-1107, 2012

28 Henderson DC, "Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality : results of a 10-year naturalistic study" 66 : 1116-1121, 2005

29 Isla Pera P, "Chronic complications of diabetes mellitus. Recommendations from the American Diabetes Association 2011. Prevention and management" 35 : 46-52, 2012

30 D’Adamo E, "Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents" 33 : 1817-1822, 2010

31 Haufe S, "Cardiorespiratory fitness and insulin sensitivity in overweight or obese subjects may be linked through intrahepatic lipid content" 59 : 1640-1647, 2010

32 Li Y, "AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice" 13 : 376-388, 2011

33 Howland RH, "A"glucose eater"drug as a therapeutic agent in psychiatry" 51 : 13-16, 2013

34 Bugianesi E, "A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease" 100 : 1082-1090, 2005